Live
- ‘Daaku Maharaaj’ to kickstart musical promotions
- ‘Game Changer’ team teases with a new promo
- Nara Lokesh emphasises overhaul of govt. schools and mid-day meal program
- Amid turmoil, air pollution peaks in Bangladesh as temperatures fall
- Google Trends unveils list of most searched ‘Indian Movies of 2024’
- BGT 2024-25: Hazlewood signals readiness for Brisbane Test after training with full run-up
- Google Presents Deep Research AI Tool for Comprehensive Web Reports
- Share of top 50 stocks to total market cap at all-time low: Report
- Nortje ruled out of SA’s remaining white-ball matches against Pakistan
- Mamata doesn't want INDIA bloc to succeed, claims BJP's Rahul Sinha
Covaxin effective against Delta Plus
Covaxin effective against Delta Plus
Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in bioRxiv by the Indian Council of Medical and Research (ICMR).
Hyderabad: Bharat Biotech's Covid-19 vaccine Covaxin (BBV152) is effective against Delta Plus (AY.1) variant of the coronavirus, according to a study published in bioRxiv by the Indian Council of Medical and Research (ICMR).
"Here, we have evaluated the IgG antibody titer and neutralizing potential of sera of Covid-19 naive individuals full doses of BBV152 vaccine, Covid-19 recovered cases with full dose vaccines and breakthrough cases post-immunization BBV152 vaccines against Delta, Delta AY.1 and B.1.617.3.," the study said.
The recent emergence of the SARS-CoV-2 Variant B.1.617.2 (Delta) variant with its high transmissibility has led to the second wave in India.
Covaxin, a whole-virion inactivated SARS-CoV-2 vaccine used for mass immunization in the country, showed a 65.2 per cent protection against the Delta variant in a double-blind, randomized, multicentre, phase 3 clinical trial.
Subsequently, Delta has further mutated to Delta AY.1, AY.2, and AY.3.
Of these, AY.1 variant was first detected in India in April 2021 and subsequently from 20 other countries as well, the study said. The study is a pre-print and has not been peer reviewed.
